Agreement - July 30, 2014
AstraZeneca signs deal with Almirall
AstraZeneca agrees strategic transaction with Almirall in respiratory disease. AstraZeneca has entered an agreement to transfer to the company the rights to Almirall’s respiratory franchise for an initial consideration of $875 million on completion, and up to $1.22 billion in development, launch, and sales-related milestones. Also, AstraZeneca has agreed to make various sales-related payments. Upon completion […]
Agreement - June 25, 2014
Oasmia in research agreement
Swedish pharmaceutical company Oasmia Pharmaceutical AB has announced that a research agreement has been signed between Oasmia and a global pharmaceutical company. The agreement relates to the use of Oasmia’s patented nanoparticle formulation technology XR-17. The full terms of the agreement have not been disclosed at this point in time. Oasmia will initially perform tests to […]
Agreement - June 24, 2014
Aurigene and Orion Corporation collaborate
Finnish pharmaceuticals company Orion Corporation and Indian biotech company Aurigene have entered into an option and research & collaboration agreement. The agreement regards rights to Aurigene’s Pan BET and Selective BET Bromodomain inhibitors program. Under the terms of the option agreement, Aurigene will receive an upfront payment from Orion, followed by a licensing fee, milestones and royalties upon exercising the option at the Candidate […]
Agreement - June 18, 2014
BioGaia enters new agreements
The Swedish health care company has signed a distribution agreement for India and an exclusive agreement in the UK. BioGaia has signed a non-exclusive agreement with Pharma Base SA for the rights to sell BioGaia’s ProTectis Baby Drops in India. Under the agreement, Pharma Base will cooperate with a local distributor for the marketing and […]
Agreement - June 16, 2014
Allenex extends agreement with Conexio Genomics
Through its subsidiary Olerup Allenex has decided to extend the agreement with the Australian company Conexio Genomics. Allenex announced a five year exclusive and global marketing and sales agreement with Conexio back in 2011 for SBT Resolver for HLA typing using the SBT technology. Software for sequence analysis had also been included in the agreement. Conexio and Allenex now […]
Agreement - June 13, 2014
AstraZeneca in lisence agreement for asthma project
The company has entered a global lisence agreement with Synairgen Plc, an AIM-listed UK company specialising in respiratory diseases. The agreement regards SNG001, a novel, inhaled interferon beta (IFN-beta) in clinical development for treating respiratory tract viral infections in patients with severe asthma. AstraZeneca will pay Synairgen a $7.25 million up-front fee and potential development, regulatory and […]
